Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions.
Pfizer Inc (PFE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance
Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 product sales and integration efforts.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter.
Pfizer raises guidance as COVID franchise drives Q3 beat
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance thanks to its COVID franchise. Read more here.
Pfizer CEO defends turnaround strategy as activist pressures management
Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.
Pfizer Rides Paxlovid Sales Growth to Better-Than-Expected Third Quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year
Pfizer sales were boosted by a COVID-19 wave during the third quarter
Pfizer (PFE) reported its third-quarter earnings on Tuesday, beating Wall Street expectations and its raising its full-year guidance thanks to a surge in demand for the pharma giant’s COVID-19 medications.
Pfizer Raises Outlook on Higher COVID-19 Drug Sales View as Third Quarter Results Beat Street
Pfizer (PFE) lifted its full-year outlook on Tuesday, driven by higher expectations for sales of its COVID-19 drugs, after the pharmaceutical giant swung to higher-than-expected earnings in the third quarter and revenue jumped 31%.
Pharmaceutical Technology7h
Pfizer boasts over 30% increase in Q3 revenues against previous year
Amidst a share value slump and executive turmoil, Pfizer reported a robust quarter thanks in part to Covid-19 drug sales.
pharmaphorum16h
Pfizer rebuffs Starboard criticism as it raises forecasts
Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...
Why is Pfizer stock falling after Q3 results?
Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...
TipRanks on MSN14h
Pfizer Inc. Reports Strong Q3 2024 Results, Raises Guidance
Pfizer Inc ( ($PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its ...
Pfizer Surpasses Q3 Expectations with Strong Earnings and Revenue Surge
In Tuesday's pre-market trade, Pfizer's ( PEE, Financial) shares edged up following a strong third-quarter earnings report ...
Pfizer: FY24 guidance includes ~$10.5B in revenue from Comirnaty, Paxlovid
The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...